Alterations in cholesterol metabolism as a risk factor for developing Alzheimer’s disease: Potential novel targets for treatment

[1]  L. Goldstein,et al.  Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons , 2019, Cell stem cell.

[2]  J. DeFelipe,et al.  27-Hydroxycholesterol Induces Aberrant Morphology and Synaptic Dysfunction in Hippocampal Neurons , 2018, Cerebral cortex.

[3]  J. Raber,et al.  Apolipoprotein E4 mediates insulin resistance-associated cerebrovascular dysfunction and the post-prandial response , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  安井 多喜雄,et al.  Cholesterol , 2019, Springer Reference Medizin.

[5]  B. Winblad,et al.  Targeting Alzheimer's disease with gene and cell therapies , 2018, Journal of internal medicine.

[6]  C. Lv,et al.  Increased Levels of 27‐Hydroxycholesterol Induced by Dietary Cholesterol in Brain Contribute to Learning and Memory Impairment in Rats , 2018, Molecular nutrition & food research.

[7]  C. Pagès,et al.  CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease , 2016, Brain : a journal of neurology.

[8]  S. Züchner,et al.  Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial , 2017, Brain : a journal of neurology.

[9]  Sandro Alves,et al.  Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future. , 2017, Human gene therapy.

[10]  G. Bu,et al.  Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes , 2017, Neuron.

[11]  G. Landreth,et al.  Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease , 2017, Neuropharmacology.

[12]  Wei Zhao,et al.  Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  Kevin M. Johnson,et al.  In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds , 2017, The Journal of Biological Chemistry.

[14]  G. Assmann,et al.  Can LDL cholesterol be too low? Possible risks of extremely low levels , 2017, Journal of internal medicine.

[15]  B. Gulyás,et al.  27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation , 2017, The Journal of experimental medicine.

[16]  K. Anstey,et al.  Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis , 2016, Journal of Alzheimer's disease : JAD.

[17]  A. Cedazo-Mínguez,et al.  Aggregation of the Inflammatory S100A8 Precedes A&bgr; Plaque Formation in Transgenic APP Mice: Positive Feedback for S100A8 and A&bgr; Productions , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[18]  J. Esteban,et al.  A diet enriched with plant sterols prevents the memory impairment induced by cholesterol loss in senescence-accelerated mice , 2016, Neurobiology of Aging.

[19]  Ji-Eun Lee,et al.  Distinct Roles of Transcription Factors KLF4, Krox20, and Peroxisome Proliferator-Activated Receptor γ in Adipogenesis , 2016, Molecular and Cellular Biology.

[20]  Huan-ling Yu,et al.  Relationship between oxysterols and mild cognitive impairment in the elderly: a case–control study , 2016, Lipids in Health and Disease.

[21]  Lars E. Borm,et al.  Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells , 2016, Cell.

[22]  C. DeCarli,et al.  Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis. , 2016, JAMA neurology.

[23]  L. Iuliano,et al.  Changes in brain oxysterols at different stages of Alzheimer's disease: Their involvement in neuroinflammation , 2016, Redox biology.

[24]  D. Balschun,et al.  Aging Triggers a Repressive Chromatin State at Bdnf Promoters in Hippocampal Neurons. , 2016, Cell reports.

[25]  Samantha Parker,et al.  Adeno-Associated Virus-Based Gene Therapy for CNS Diseases , 2016, Human gene therapy.

[26]  D. Holtzman,et al.  A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects , 2016, Alzheimer's & dementia.

[27]  Ling Chen,et al.  Atorvastatin in improvement of cognitive impairments caused by amyloid β in mice: involvement of inflammatory reaction , 2016, BMC Neurology.

[28]  C. Pagès,et al.  CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease , 2016, Brain : a journal of neurology.

[29]  P. Passmore,et al.  Statins for the prevention of dementia. , 2016, The Cochrane database of systematic reviews.

[30]  Ji-Eun Lee,et al.  Distinct roles of transcription factors KLF4, Krox20 and PPARγ in adipogenesis , 2016 .

[31]  S. Kuo,et al.  Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis. , 2016, Journal of Alzheimer's disease : JAD.

[32]  P. Dutar,et al.  Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. , 2015, Human molecular genetics.

[33]  M. Aronson,et al.  Do statins prevent Alzheimer's disease? A narrative review. , 2015, European journal of internal medicine.

[34]  Keith A. Johnson,et al.  Modulation of TREM2 by CD33: a protein QTL study integrates Alzheimer loci in human monocytes , 2016 .

[35]  I. Pikuleva,et al.  Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy , 2015, Molecular Pharmacology.

[36]  A. Saykin,et al.  Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans. , 2015, Ethnicity & disease.

[37]  R. Miles,et al.  CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. , 2015, Brain : a journal of neurology.

[38]  O. Ghribi,et al.  Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease–Parkinson's disease overlap? , 2015, Experimental Gerontology.

[39]  G. Poli,et al.  Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease , 2015, Front. Aging Neurosci..

[40]  E. Gill,et al.  Statins and the liver. , 2015, Cardiology clinics.

[41]  R. Blumenthal,et al.  Cholesterol, Statins, and Dementia: What the Cardiologist Should Know , 2015, Clinical cardiology.

[42]  G. Poli,et al.  Relation between TLR4/NF-κB signaling pathway activation by 27-hydroxycholesterol and 4-hydroxynonenal, and atherosclerotic plaque instability , 2015, Aging cell.

[43]  B. Winblad,et al.  27-Hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice , 2015, Behavioural Brain Research.

[44]  R. Miles,et al.  CYP 46 A 1 inhibition , brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer ’ s disease , 2015 .

[45]  L. Fenart,et al.  Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier. , 2015, Journal of Alzheimer's disease : JAD.

[46]  Juan Zhang,et al.  Cholesterol metabolism and homeostasis in the brain , 2015, Protein & Cell.

[47]  D. Mikhailidis,et al.  Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. , 2014, Current pharmaceutical design.

[48]  E. Gold,et al.  25-Hydroxycholesterol acts as an amplifier of inflammatory signaling , 2014, Proceedings of the National Academy of Sciences.

[49]  C. Betsholtz,et al.  Effects of a Disrupted Blood-Brain Barrier on Cholesterol Homeostasis in the Brain* , 2014, The Journal of Biological Chemistry.

[50]  D. Balschun,et al.  Constitutive hippocampal cholesterol loss underlies poor cognition in old rodents , 2014, EMBO molecular medicine.

[51]  Lei Zhang,et al.  In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. , 2014, Cell stem cell.

[52]  C. DeCarli,et al.  Associations between serum cholesterol levels and cerebral amyloidosis. , 2014, JAMA neurology.

[53]  A. Gomes,et al.  Cholesterol 24S-Hydroxylase Overexpression Inhibits the Liver X Receptor (LXR) Pathway by Activating Small Guanosine Triphosphate-Binding Proteins (sGTPases) in Neuronal Cells , 2014, Molecular Neurobiology.

[54]  Cindee M. Madison,et al.  Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. , 2013, JAMA neurology.

[55]  L. Girard,et al.  27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. , 2013, Cell reports.

[56]  Gabriel M. Belfort,et al.  The Major Brain Cholesterol Metabolite 24(S)-Hydroxycholesterol Is a Potent Allosteric Modulator of N-Methyl-d-Aspartate Receptors , 2013, The Journal of Neuroscience.

[57]  H. Koek,et al.  The influence of vascular risk factors on cognitive decline in patients with dementia: a systematic review. , 2013, Maturitas.

[58]  A. Cedazo-Mínguez,et al.  Is It Possible to Improve Memory Function by Upregulation of the Cholesterol 24S-Hydroxylase (CYP46A1) in the Brain? , 2013, PloS one.

[59]  J. DeFelipe,et al.  The influence of phospho-tau on dendritic spines of cortical pyramidal neurons in patients with Alzheimer’s disease , 2013, Brain : a journal of neurology.

[60]  Jure Acimovic,et al.  On the regulatory role of side-chain hydroxylated oxysterols in the brain. Lessons from CYP27A1 transgenic and Cyp27a1−/− mice1 , 2013, Journal of Lipid Research.

[61]  J. Kim,et al.  Hypercholesterolemia accelerates amyloid β-induced cognitive deficits. , 2013, International journal of molecular medicine.

[62]  J. Chen,et al.  Cholesterol efflux is differentially regulated in neurons and astrocytes: implications for brain cholesterol homeostasis. , 2013, Biochimica et biophysica acta.

[63]  Bryony Jones.  Alzheimer disease: TREM2 linked to late-onset AD , 2013, Nature Reviews Neurology.

[64]  O. Ghribi,et al.  Endoplasmic reticulum stress-induced CHOP activation mediates the down-regulation of leptin in human neuroblastoma SH-SY5Y cells treated with the oxysterol 27-hydroxycholesterol. , 2012, Cellular signalling.

[65]  Bo Torben Porse,et al.  Psd-95 is post-transcriptionally repressed during early neural development by PTBP1 and PTBP2 , 2011, Nature Neuroscience.

[66]  R. Rimondini,et al.  Combination of apolipoprotein E4 and high carbohydrate diet reduces hippocampal BDNF and arc levels and impairs memory in young mice. , 2012, Journal of Alzheimer's disease : JAD.

[67]  D. Selkoe,et al.  Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. , 2011, Archives of neurology.

[68]  Carolyn D. DuSell,et al.  The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors. , 2011, Endocrinology.

[69]  C. Dotti,et al.  Cellular stress from excitatory neurotransmission contributes to cholesterol loss in hippocampal neurons aging in vitro , 2011, Neurobiology of Aging.

[70]  R. Schüle,et al.  Side Chain-oxidized Oxysterols Regulate the Brain Renin-Angiotensin System through a Liver X Receptor-dependent Mechanism* , 2011, The Journal of Biological Chemistry.

[71]  B. Winblad,et al.  Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation , 2011, Journal of Lipid Research.

[72]  A. Cedazo-Mínguez,et al.  Plasma cholesterol and risk for late-onset Alzheimer’s disease , 2011, Expert review of neurotherapeutics.

[73]  P. Shaul,et al.  27-Hydroxycholesterol: the first identified endogenous SERM , 2011, Trends in Endocrinology & Metabolism.

[74]  P. V. Van Veldhoven,et al.  Regulation of tyrosine kinase B activity by the Cyp46/cholesterol loss pathway in mature hippocampal neurons: relevance for neuronal survival under stress and in aging , 2011, Journal of neurochemistry.

[75]  A. von Eckardstein,et al.  Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. , 2011, Atherosclerosis.

[76]  Bengt Winblad,et al.  Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[77]  K. Leenders,et al.  Typical cerebral metabolic patterns in neurodegenerative brain diseases , 2010, Movement disorders : official journal of the Movement Disorder Society.

[78]  A. Işık,et al.  Late onset Alzheimer’s disease in older people , 2010, Clinical interventions in aging.

[79]  Carolyn D. DuSell,et al.  The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. , 2010, Endocrinology.

[80]  J. Gustafsson,et al.  Neuropathologic and Biochemical Changes During Disease Progression in Liver X Receptor &bgr;−/− Mice, A Model of Adult Neuron Disease , 2010, Journal of neuropathology and experimental neurology.

[81]  Anton P. Porsteinsson,et al.  Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related Disorders , 2010, Biological Psychiatry.

[82]  Pierre Bougnères,et al.  Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  O. Ghribi,et al.  Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. , 2010, Journal of Alzheimer's disease : JAD.

[84]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[85]  Steve Meaney,et al.  Oxysterols and neurodegenerative diseases. , 2009, Molecular aspects of medicine.

[86]  F. Jessen,et al.  CYP46A1 variants influence Alzheimer’s disease risk and brain cholesterol metabolism , 2009, European Psychiatry.

[87]  Suzanne Craft,et al.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. , 2009, Archives of neurology.

[88]  S. Akterin,et al.  Activity‐Regulated Cytoskeleton‐Associated Protein in Rodent Brain is Down‐Regulated by High Fat Diet in vivo and by 27‐Hydroxycholesterol in vitro , 2009, Brain pathology.

[89]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[90]  Prasanthi,et al.  Molecular Neurodegeneration Differential Effects of 24-hydroxycholesterol and 27-hydroxycholesterol on Β-amyloid Precursor Protein Levels and Processing in Human Neuroblastoma Sh-sy5y Cells , 2022 .

[91]  A. Faden,et al.  Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain. , 2008, Journal of neurotrauma.

[92]  D. Russell,et al.  Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation , 2008, Proceedings of the National Academy of Sciences.

[93]  G. D’Arcangelo,et al.  Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus , 2008, Experimental Neurology.

[94]  J D Kalbfleisch,et al.  Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study , 2008, Neurology.

[95]  H. Bimonte-Nelson,et al.  High cholesterol‐induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice , 2008, Journal of neurochemistry.

[96]  Peter Tontonoz,et al.  Integration of metabolism and inflammation by lipid-activated nuclear receptors , 2008, Nature.

[97]  K. Anstey,et al.  Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[98]  A. Tall,et al.  ATP‐binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[99]  O. Hanon,et al.  Vascular risk factors, cognitve decline, and dementia , 2008, Vascular health and risk management.

[100]  R. Mayeux,et al.  Plasma Lipid Levels in the Elderly Are Not Associated with the Risk of Mild Cognitive Impairment , 2008, Dementia and Geriatric Cognitive Disorders.

[101]  O. Ghribi.  Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. , 2008, Journal of Alzheimer's disease : JAD.

[102]  K. Hall,et al.  Association of statin use with cognitive decline in elderly African Americans , 2007, Neurology.

[103]  A. Nordberg,et al.  Regulation of α- and β-secretase activity by oxysterols: Cerebrosterol stimulates processing of APP via the α-secretase pathway , 2007 .

[104]  A. Ogura,et al.  Brain-Derived Neurotrophic Factor Regulates Cholesterol Metabolism for Synapse Development , 2007, The Journal of Neuroscience.

[105]  Joseph L. Goldstein,et al.  Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Oxysterols block transport by binding to Insig , 2007, Proceedings of the National Academy of Sciences.

[106]  Wolfgang Sattler,et al.  Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7α-hydroxy-3-oxo-4-cholestenoic acid Published, JLR Papers in Press, January 24, 2007. , 2007, Journal of Lipid Research.

[107]  L. Costa,et al.  Cholesterol homeostasis in the developing brain: a possible new target for ethanol , 2007, Human & experimental toxicology.

[108]  S. Paul,et al.  Liver X Receptor-Mediated Gene Regulation and Cholesterol Homeostasis in Brain: Relevance to Alzheimers Disease Therapeutics , 2007 .

[109]  H. Soininen,et al.  Serum cholesterol changes after midlife and late-life cognition , 2007, Neurology.

[110]  I. Björkhem,et al.  Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain , 2006, Journal of internal medicine.

[111]  M. Schrag,et al.  Deposition of iron and β‐amyloid plaques is associated with cortical cellular damage in rabbits fed with long‐term cholesterol‐enriched diets , 2006, Journal of neurochemistry.

[112]  Henrik Zetterberg,et al.  Alzheimer's disease , 2006, The Lancet.

[113]  M. Kivipelto,et al.  Cholesterol as a risk factor for Alzheimer's disease – epidemiological evidence , 2006, Acta neurologica Scandinavica. Supplementum.

[114]  Miia Kivipelto,et al.  Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment? , 2006, Neuroscience Letters.

[115]  O. Halbach,et al.  The CNS renin-angiotensin system , 2006, Cell and Tissue Research.

[116]  Brad E. Pfeiffer,et al.  Brain cholesterol turnover required for geranylgeraniol production and learning in mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[117]  L. Ekström,et al.  Studies on the Transcriptional Regulation of Cholesterol 24-Hydroxylase (CYP46A1) , 2006, Journal of Biological Chemistry.

[118]  Joseph L. Goldstein,et al.  Protein Sensors for Membrane Sterols , 2006, Cell.

[119]  R. Mayeux,et al.  Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer's disease , 2006, Neuroscience Letters.

[120]  M. D. de Pancorbo,et al.  Polymorphism in the Cholesterol 24S-Hydroxylase Gene (CYP46A1) Associated with the APOEυ3 Allele Increases the Risk of Alzheimer’s Disease and of Mild Cognitive Impairment Progressing to Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[121]  M. Kivipelto,et al.  High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice , 2005, FEBS letters.

[122]  G. Feuerstein,et al.  Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. , 2005, American journal of hypertension.

[123]  Hilkka Soininen,et al.  Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.

[124]  B. Winblad,et al.  The age-dependent relation of blood pressure to cognitive function and dementia , 2005, The Lancet Neurology.

[125]  M. M. Mielke,et al.  High total cholesterol levels in late life associated with a reduced risk of dementia , 2005, Neurology.

[126]  G. Mandel,et al.  REST and Its Corepressors Mediate Plasticity of Neuronal Gene Chromatin throughout Neurogenesis , 2005, Cell.

[127]  M. Eriksson,et al.  Patients with atherosclerosis may have increased circulating levels of 27‐hydroxycholesterol and cholestenoic acid , 2005, Scandinavian journal of clinical and laboratory investigation.

[128]  M. Pancorbo,et al.  Polymorphism in the Cholesterol 24 S-Hydroxylase Gene ( CYP 46 A 1 ) Associated with the APOE 3 Allele Increases the Risk of Alzheimer ’ s Disease and of Mild Cognitive Impairment Progressing to Alzheimer ’ s Disease , 2005 .

[129]  J. Flory,et al.  Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. , 2004, The American journal of medicine.

[130]  Ze Yang,et al.  Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese , 2004, Neuroscience Letters.

[131]  K. Niwa,et al.  Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression , 2004, Neurology.

[132]  C. Eckman,et al.  Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease* , 2004, Journal of Biological Chemistry.

[133]  C. Caltagirone,et al.  Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators , 2004, Neurobiology of Aging.

[134]  K. Fassbender,et al.  High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs , 2004, Steroids.

[135]  Eric J Topol,et al.  Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins , 2004, The Lancet.

[136]  S. Love,et al.  APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease. , 2004 .

[137]  T. Bayer,et al.  Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease Published, JLR Papers in Press, October 1, 2003. DOI 10.1194/jlr.M300320-JLR200 , 2004, Journal of Lipid Research.

[138]  V. Olkkonen,et al.  Oxysterols and oxysterol binding proteins: role in lipid metabolism and atherosclerosis , 2004, Annals of medicine.

[139]  Joseph L Goldstein,et al.  Insig-dependent Ubiquitination and Degradation of Mammalian 3-Hydroxy-3-methylglutaryl-CoA Reductase Stimulated by Sterols and Geranylgeraniol* , 2003, Journal of Biological Chemistry.

[140]  A. Levy,et al.  A Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD): Study Methods and Baseline Results , 2003, Neuroepidemiology.

[141]  F. Pfrieger,et al.  Cholesterol homeostasis and function in neurons of the central nervous system , 2003, Cellular and Molecular Life Sciences CMLS.

[142]  I. Björkhem,et al.  Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers Published, JLR Papers in Press, February 1, 2003. DOI 10.1194/jlr.M200434-JLR200 , 2003, Journal of Lipid Research.

[143]  I. Björkhem,et al.  On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation Published, JLR Papers in Press, September 16, 2000. DOI 10.1194/jlr.M200293-JLR200 , 2002, Journal of Lipid Research.

[144]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[145]  Philippe Renou,et al.  [Vascular risk factors]. , 2002, Presse medicale.

[146]  V. Meiner,et al.  Human Sterol 27-Hydroxylase (CYP27) Overexpressor Transgenic Mouse Model , 2002, The Journal of Biological Chemistry.

[147]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[148]  J. Leverenz,et al.  Diet-induced hypercholesterolemia enhances brain A&bgr; accumulation in transgenic mice , 2002, Neuroreport.

[149]  R. Dean,et al.  Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. , 2002, The American journal of pathology.

[150]  F. Jessen,et al.  Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease , 2002, Molecular Psychiatry.

[151]  B. Winblad,et al.  On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells , 2001, Neuroscience Letters.

[152]  R. Hellweg,et al.  Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures , 2001, Neuroscience.

[153]  A. Koudinov,et al.  Essential role for cholesterol in synaptic plasticity and neuronal degeneration , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[154]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[155]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[156]  D. Russell,et al.  Expression Cloning of an Oxysterol 7α-Hydroxylase Selective for 24-Hydroxycholesterol* , 2000, The Journal of Biological Chemistry.

[157]  K. Matthews,et al.  Effects of lovastatin on cognitive function and psychological well-being. , 2000, The American journal of medicine.

[158]  L. Bretillon,et al.  Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. , 2000, Journal of lipid research.

[159]  F. Jessen,et al.  Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. , 2000, Journal of lipid research.

[160]  J M Guileyardo,et al.  cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[161]  K Kobylarz,et al.  Acute cholesterol depletion inhibits clathrin-coated pit budding. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[162]  M. Michikawa,et al.  Inhibition of Cholesterol Production but Not of Nonsterol Isoprenoid Products Induces Neuronal Cell Death , 1999, Journal of neurochemistry.

[163]  J. Wahren,et al.  Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. , 1998, Journal of lipid research.

[164]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[165]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[166]  N. Santanello,et al.  Effect of Pharmacologic Lipid Lowering on Health‐Related Quality of Life in Older Persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study , 1997, Journal of the American Geriatrics Society.

[167]  D. Lütjohann,et al.  Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[168]  R Lujan,et al.  Perisynaptic Location of Metabotropic Glutamate Receptors mGluR1 and mGluR5 on Dendrites and Dendritic Spines in the Rat Hippocampus , 1996, The European journal of neuroscience.

[169]  J. Mason,et al.  A Novel Cytochrome P450 Expressed Primarily in Brain (*) , 1995, The Journal of Biological Chemistry.

[170]  M. Prince.  Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia. , 1995, Journal of psychosomatic research.

[171]  Stephen W. Scheff,et al.  Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol , 1994, Experimental Neurology.

[172]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[173]  D. Russell,et al.  Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. , 1991, The Journal of biological chemistry.

[174]  H. Jörnvall,et al.  Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. , 1989, The Journal of biological chemistry.

[175]  R. Mahley,et al.  Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. , 1987, Biochimica et biophysica acta.

[176]  J. Taylor,et al.  Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. , 1985, The Journal of clinical investigation.

[177]  L. Iversen,et al.  ARGININE VASOPRESSIN AND CHOLINE ACETYLTRANSFERASE IN BRAINS OF PATIENTS WITH ALZHEIMER TYPE SENILE DEMENTIA , 1980, The Lancet.

[178]  A. Murdoch.  Cloning , 2007, Ethics & Medics.